Meet the Exhibitors

Agendia is a leading provider of innovative precision oncology solutions for early-stage breast cancer. Using advanced genomic assays like MammaPrint and BluePrint, Agendia helps clinicians identify the most effective treatment plan, minimizing risks of over- and undertreatment. With cutting-edge technology and a commitment to innovation, Agendia strives to shape the future of precision oncology and illuminate the path forward in breast cancer care.

Ambry Genetics translates scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind genetic disease. It is a leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease. Its unparalleled track record of discoveries over 25 years, and growing database that continues to expand in collaboration with academic, corporate, and pharmaceutical partners, means Ambry Genetics is first to market with innovative products and comprehensive analysis that enable clinicians to confidently inform patient health decisions.

American Breast Care is a leading producer of post-mastectomy products supplying: compression garments, mastectomy bras, breast forms, custom prostheses, post-surgical products, and accessories worldwide. At ABC, we take pride in our commitment to the amazing women that we serve. Our goal is not only to provide quality products & education, but to facilitate a positive & impactful experience in the lives of those within our reach.

From high quality, comfortable breast forms, to functional and fashionable bras to post-surgery and leisure products, ABC has the products your patients deserve and need.

For 50 years, we have passionately pursued our goal of giving women their full self-confidence after breast cancer. Since 1975, we have supported women as a proficient partner in breast care, with the highest standards in quality, innovation and design. Patents for materials and manufacturing methods are proof of our progress. However, this is by no means the end of the story. In the future, we will continue to listen carefully to the women touched by breast cancer, and to our specialist retailers, and we will continue to develop our product portfolio. All of our products are perfectly tailored to the needs of women with breast cancer - to date, we have sold over 17 million breast forms and 34 million breast care textiles. We are proud to accompany women throughout their recovery journeys, from diagnosis to a return to normal life.

AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.

AI-Enhanced Ultrasound-Guided Localization for Breast Cancer Surgery

AURA develops AI-enhanced software that integrates with existing ultrasound systems to provide precise guidance for breast cancer surgery. The technology detects existing biopsy clips during surgery, eliminating the need for additional pre-surgical localization devices like wires or seeds. This streamlines workflow, reduces costs, and improves patient experience. Future development will expand capabilities to include direct tumor visualization. TECHNOLOGY AURA's IntraGuide software combines advanced algorithms and machine learning models to analyze ultrasound images and RF data in real-time. The system integrates seamlessly with existing ultrasound equipment and operates through an intuitive tablet interface, allowing surgeons to adjust image quality as needed. The algorithm has been developed using over 500,000 ultrasound images and different types of biopsy clips. The technology enables immediate image visualization without the extensive training typically required to read ultrasound images. CLINICAL NEED Precise tumor localization is critical for breast cancer surgery. Current methods require pre-surgical insertion of wires or seeds to mark non-palpable tumors. Wire-guided localization, while cost-effective, requires same-day or day-before procedures and risks displacement, causing patient discomfort. Radioactive seeds, though inexpensive, face limited adoption due to safety concerns. Other techniques show good results but require high upfront costs and additional invasive procedures, risking complications. Intraoperative ultrasound (IOUS) improves surgical outcomes and reduces re-operations, but its adoption is limited by the steep learning curve in ultrasound interpretation SIGNIFICANCE AURA's IntraGuide represents a first-of-its-kind solution that transforms standard biopsy clips into surgical guidance markers. By detecting clips already placed during biopsy, the technology elimi

bcalmed, Inc., a 501(c)(3) non-profit, and the bcalmed bag were created to help patients manage post-operative drains after surgical procedures such as mastectomies and lumpectomies. The bcalmed bag is provided free of charge to any patient to ease their journey to recovery.

At Beekley Medical, our goal is to help positively impact patients' lives and improve clinical outcomes. We have a high commitment to investing in the research and development of simple, low cost, disposable products that help medical imaging, surgical, and radiation oncology professionals improve communication, productivity, and patient care.

We partner with our customers, clinicians, and inventors to produce professional products that replace makeshift or improve upon current methods. Our industries are carefully monitored to ensure our products meet tomorrow’s needs today.

Best Medical International (BMI), a TeamBest Global company, is part of a family of trusted companies and organizations with a proven track record of innovation, quality and service in external beam radiation therapy, brachytherapy and vascular brachytherapy solutions. BMI manufactures and supplies Iodine-125 and Palladium-103 seeds, needles, templates, applicators, catheters, fiducial markers, and a variety of other products for brachytherapy and other radiation therapy applications. BMI aims to be the one partner clinicians turn to for all their radiation therapy and oncology product and service requirements.

CancerIQ has a bold vision to end cancer as we know it by empowering health systems to scale early cancer detection and prevention to all patient populations. The CancerIQ platform makes it easy to gather comprehensive patient data, automatically map it to the latest evidence-based guidelines, and manage hyper-personalized care plans within existing EHR workflows. We help breast centers identify more patients who would benefit from preventive care, improving patient outcomes, lowering the cost of care and driving downstream revenue.

At Cardinal Health Nuclear & Precision Health Solutions, we provide essential products and services that support providers in caring for their patients. Our portfolio of radiopharmaceuticals includes agents used in lymphatic mapping and guiding sentinel lymph node biopsies in patients with breast cancer. Visit us at booth 219 to learn more!

Care Wise has many years of experience and expertise working in the specialist health sector. Indeed, as part of the LabLogic group, the company is a key supplier to the healthcare sector worldwide.

We are the manufacturer of the Care Wise C-Trak Apollo Gamma Probe which provides accurate and precise detection of radiation for use during sentinel node biopsies in breast, melanoma and other types of cancer. Offering superior sensitivity and directionality via wired or wireless connectivity with the same probe allows complete flexibility in the operating room.

Using our proven OmniProbe® technology, the Apollo offers precise and accurate detection of various isotopes. Its superior directionality means quick and accurate identification of subjects which leads to less dissection and improved procedures.

Software for the C-Trak Apollo has many features including autoranging capabilities, choice of four audible signals, easier switching between isotopes (such as Tc-99m and I-125), storage of calibration tests

For nearly 50 years, CARTI has been dedicated to redefining cancer care, offering a full spectrum of services designed to support patients through every stage of their journey. As a not-for-profit multidisciplinary cancer care provider, CARTI brings together expert physicians, advanced technology and a compassionate approach to deliver comprehensive treatment. With a network of locations across Arkansas including the state's first cancer-focused surgery center, CARTI ensures that high-quality patient-centered care is always within reach.

CARTI’s commitment to breast cancer care extends beyond treatment. Our expert team of breast surgical oncologists, medical oncologists, radiation oncologists, genetic counselors and supportive care specialists work collaboratively to provide individualized evidence-based treatment plans. The Breast Center at CARTI offers a full range of services including advanced imaging, 3D mammography, breast MRI, ultrasound, biopsy and surgical management of both benign and cancerous conditions. By integrating the latest advancements with a personalized patient-first approach, we empower women with knowledge, confidence and compassionate support at every step.

Our belief in whole-patient care is reflected in the resources available to support those facing a breast cancer diagnosis. CARTI’s comprehensive survivorship programs, genetic counseling services, lymphedema therapy and wellness initiatives ensure that patients have access to the tools they need to navigate treatment and recovery. The Bridge at CARTI, our patient support program, offers financial advocacy, counseling, wellness services and a salon and appearance center—because we understand that cancer care goes beyond medicine.

At CARTI, we are more than a cancer treatment provider—we are a trusted partner in care committed to innovation, accessibility and the best possible outcomes for every patient.

CooperSurgical® is a leading women’s healthcare company dedicated to putting time on the side of women, babies and families at the healthcare moments that matter most in life. CooperSurgical® has evolved its portfolio of over 600 products to include key products and services used primarily by obstetricians, nurses, certified nurse midwives and their related surgical subspecialties

We are the global leader in patient radiotherapy positioning and healthcare innovations that advance human care. From researchers and scientists to designers and developers, CQ Medical is at the forefront of cutting-edge, patient-centric medical technology designed to deliver the best possible outcomes.

Designs for Vision, Inc. manufacturers Surgical Loupes and Surgical Headlights. Our products enhance the vision of clinicians through magnification and illumination. Designs for Vision has been established since 1961 and is the world’s leading manufacturer of wearable magnification and illumination devices for surgeons. Designs for Vision’s Loupes & Headlights are utilized world-wide in all surgical specialties.

Dilon Technologies® Inc. is a medical device manufacturer that benefits patients around the world with products providing: real-time margin assessment, advanced hemostasis, lymphatic mapping, intra-operative specimen analysis, and a portable video laryngoscope. These products address breast and other surgical specialties’ needs yielding positive patient outcomes.

Lilly unites caring with discovery to create medicines that make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer's disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.

Envisio by Elucent is a cutting-edge surgical guidance technology designed to transform breast cancer care. Leveraging continuous, true three-dimensional spatial awareness, Envisio provides unparalleled precision during tumor localization and excision. The system integrates seamlessly into the surgical workflow, offering surgeons a clearer view and greater control while supporting oncoplastic techniques for optimal cosmetic and clinical outcomes.

Save time, see more patients, level up your practice. We help oncologists operate at the top of their license by automating large amounts of patient admin and education, allowing you to run more efficiently and deliver a better experience to your patients.

The result? Your people have room to breathe and work at their best. Your patients are comfortable and confident. Your practice thrives.

Esaote provides fully-featured, scalable ultrasound solutions for a wide variety of clinical applications. Esaote draws upon almost 40 years of experience in providing cutting-edge imaging solutions centered on superior image quality. Esaote offers a system to fit all your clinical needs from portable to feature-rich, console ultrasound systems.

Esaote, founded in 1978 in Genoa, Italy, has firmly established itself as a leading developer of diagnostic ultrasound systems for over 40 years. The company gained significant recognition in 1980 with the launch of its first compact echocardiography system, embarking on a mission to create innovative and portable devices that deliver high-quality ultrasound systems at affordable prices.

A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis.

About GE HealthCare Technologies Inc. GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits. Follow us on LinkedIn, X (formerly Twitter), Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com/ for more information.

Hackensack Meridian Health is the leading not-for-profit health care network in New Jersey offering a complete range of medical services, innovative research, and life-enhancing care aiming to serve as a national model for changing and simplifying health care delivery through partnerships with innovative companies and focusing on quality and safety.

Hoag is proud to train the next generation of Oncoplastic breast surgeons as the first Advanced Oncoplastic Breast Fellowship program in the United States. This one-year program in Newport Beach, CA will provide a broad multi-disciplinary clinical experience in all aspects of oncoplastic breast surgery.

Fellows will receive in depth exposure in breast surgery, plastics, and reconstructive surgery. The surgical training experience will cover level 1 and level 2 oncoplastic procedures. Breast imaging exposure includes training and didactics with fellowship trained breast imagers with experience in mammography, breast ultrasound, breast MRI, and various biopsy techniques. Graduates of the Oncoplastic Breast Fellowship at Hoag will have the tools and experience to qualify for ASBrS Oncoplastic Surgery certification.

Fellows can expect to complete an average of 350-400 oncoplastic surgery cases during their training year. Fellows will gain comprehensive experience in managing a variety of diagnoses, including invasive cancer, DCIS, benign conditions, and high-risk lesions. Fellows will perform diverse procedures including level 1 oncoplastic glandular advancement/rearrangement, crescent mastopexy, batwing, donut/Benelli mastopexy and level 2 circumvertical mastopexy and wise pattern reduction mammaplasty, and high level exposure to level 3 procedures involving volume replacement with LICAP, AICAP, etc. Additionally, fellows will gain experience in sentinel lymph node biopsy, and axillary lymph node dissection and master various mastectomy techniques (simple, nipple sparing, skin sparing, Goldilocks).

To learn more about the fellowship, please visit our website: www.hoag.org/oncoplasticbreast Applications are now being accepted for the 2026-2027 academic year. Please review the “Application Information” tab of our webpage that includes information on how to apply.

We look forward to hearing from you!

Hologic is a global medical technology company specializing in women’s health and well-being. We offer innovative solutions for screening, detecting and treating conditions and diseases that affect women throughout their lives, including breast, gynecological and skeletal issues; cervical cancer testing and sexually transmitted diseases. As a science-driven company, our products are backed by clinical evidence, ensuring that they perform as intended, so healthcare professionals can have greater certainty in their decisions and patients, greater peace of mind.

IC Surgical’s transformative new technology, Interi System, has been shown to reduce post-surgical complications such as seroma and flap necrosis and improve internal wound healing in post-mastectomy breast reconstruction. The Interi System delivers consistent, continuous suction pressure across a wide area deep in the tissue planes following surgery. For the first time, Interi provides surgeons with a tool to actively control wounds at the internal surgical site.

IceCure is transforming women’s health by bringing the choice of advanced minimally invasive cryoablation to breast care. Our ProSense® System uses liquid-nitrogen to generate ultra cold temperatures to destroy tumors by freezing them. ProSense® empowers patients with the choice of a less invasive, office-based procedure.

The ICE3 trial sponsored by IceCure was the largest multi-center clinical trial to have been completed with liquid nitrogen-based cryoablation for patients with low-risk, early-stage breast cancer without excision. For the subgroup of patients (108 out of 194) who received cryoablation with ProSense and endocrine therapy only, the IBTR was 3.7% and breast cancer survival was 96.1%. Both patients and physicians reported high satisfaction with the procedure.

In November 2024, an FDA advisory panel voted in favor of the benefit-risk profile for ProSense® Cryoablation in Early-Stage Low Risk Breast Cancer. IceCure has filed for FDA marketing authorization of ProSense for treating patients with early-stage, low risk invasive breast cancer with cryoablation and adjuvant endocrine therapy. A decision is expected within the first half of 2025.

ProSense® currently has FDA clearance for use as a cryosurgical tool in the destruction of fibroadenomas and in the fields of general surgery, thoracic surgery, gynecology, oncology, proctology, and urology. The system is CE-marked and is available across several European and East Asian countries, Brazil, and India.

ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximize patient health. The SOZO® Digital Health Platform, the world's most advanced, noninvasive BIS device, delivers a precise snapshot of fluid status and tissue composition for lymphedema & body composition assessment - all in less than 30 seconds. Offer your patients peace of mind. Know their L-Dex® score with the leading technology for point-of-care lymphedema and body composition assessment. Learn more: www.impedimed.com

INFINITY- The world's best massage chair

In today's culture, we place more emphasis on our wellness than ever before. After all, a higher level of overall well-being leads to a higher quality of life, which better equips us to conquer our limitations and enjoy doing the things we love most. At Infinity, we aim to help people of all lifestyles do just that. Our mission is to improve the health and wellness of our customers to live more comfortably and make the most of every day.

Experience relaxation with INFINITY- The world's best massage chair

Innoblative is a private medical device company addressing clinical unmet needs for patients with breast cancer and other soft tissue diseases. We are developing advanced energy-based surgical solutions to help improve the way surgeons coagulate and ablate soft tissue to achieve better care for patients. Innoblative has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the company’s SIRA® RFA Electrosurgical Device.

Medical device manufacturer.

iSono Health is advancing breast breast imaging with ATUSA, the FDA-cleared, AI-powered robotic 3D ultrasound. ATUSA's automated, portable system offers Ultrasound-as-a-Service (USaaS) at the point of care, filling critical gaps where mammography often falls short, especially in dense breast tissue. We solve access issue with low cost and easily accessible without sonographer at the point of care. Think virtual sonographer!

Koning is a global Health Technology company focused on improving the breast imaging industry with its patented Koning Vera Breast CT (KBCT). The Koning Vera is a TRUE 3D imaging device that takes 7 seconds per breast, at radiation doses comparable to conventional mammograms. Koning's vision is to create a revolution in medical imaging through advanced computed tomography technology that dramatically improves the way clinicians visualize and evaluate breast tissue. The Koning Vera is expected to optimize early disease detection, diagnosis, intervention, and treatment, and will improve survival rates for millions of patients worldwide.

At KUBTEC®, our passion is developing transformative technologies that enable precision cancer surgery. For nearly 20 years, we have led the way in specimen imaging technology, and now we also offer an innovative gamma probe detection system that seamlessly integrates with our imaging solutions.

As a family-owned company, headquartered in Connecticut, USA, our dedication to improving care goes beyond exceptional products - we take immense pride in delivering unparalleled service and support to all our customers across the globe.

Lumicell is a privately held life sciences company revolutionizing the intraoperative detection of cancer with its real-time fluorescence imaging technology. Lumicell’s proprietary technology is FDA-approved for use in the treatment of breast cancer.

At Mammotome, we provide innovative technology to help clinicians accurately diagnose breast cancer, always keeping the patient at the heart of our mission. Our reliable and user-friendly products enhance workflow efficiency and diagnostic confidence. Our portfolio includes Mammotome breast biopsy devices, tissue markers, the Neoprobe® Gamma Detection System, and the Sirius Medical Pintuition® Localization System.

For more information, visit mammotome.com and follow us on Facebook, LinkedIn, and X.

Masthead® was founded in 2012 with a singular mission: to provide patients with comfort, support, and dignity as they prepare for, undergo, and recover from surgery and other treatments.

Our state-of-the-art Elizabeth Pink Surgical Bra® --known as “The pink one”--and other Masthead® surgical garments are used every day by the finest doctors and surgical staffs in hundreds of the top hospitals in the country.

Helping you provide the best care to your patients is our mission. Join the hundreds of providers who have improved their patients’ experience by supplying them with Masthead® products.

Bold thinking. Bolder actions. We are Medtronic. We lead global healthcare technology and boldly attack the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. Learn more at www.medtronic.com

At Merit Oncology, we are committed to easing the burden that cancer places on patients and their loved ones by developing unparalleled technologies to improve the treatment process for patients and physicians.

The Myriad Oncology portfolio of advanced genetic and tumor genomic testing solutions is designed to meet the unique needs of oncology specialists and their patients across each step in the patient care continuum. Myriad Oncology solutions include risk assessment, screening, tools to aid treatment guidance, and survivorship planning. Backed by best-in-industry clinician support services and robust patient education resources, Myriad Oncology empowers oncology specialists with the personalized answers they expect to make confident decisions.

Signatera Residual Disease (MRD) test is a custom-built circulating tumor DNA (ctDNA) test for molecular residual disease (MRD) assessment and treatment response monitoring in patients previously diagnosed with cancer. The SignateraTM test is personalized and tumor-informed, providing each individual with a customized blood test tailored to fit the unique signature of clonal mutations found in that individual’s tumor. This maximizes Signatera’s accuracy for detecting the presence or absence of residual disease in a blood sample, even at levels down to a single tumor molecule in a tube of blood. Signatera is intended to detect and assess how much cancer is left in the body, to identify recurrence earlier and to help optimize treatment decisions.

Not Putting on a Shirt is a 501(c)(3) patient advocacy nonprofit promoting an optimal standard of care for patients going flat after mastectomy (aesthetic flat closure, or AFC). NPOAS provides education, tools, and peer support to empower patients and educate medical providers, supports research on AFC, and conducts institutional advocacy to improve outcomes for patients. Visit our website to learn more, order free brochures, or find a flat friendly surgeon near you!

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

Pacira BioSciences, Inc. is the industry leader in its commitment to non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. To learn more about our mission to reduce overreliance on opioids, visit www.pacira.com.

Perimeter Medical Imaging AI is a medical technology company driven to transform cancer surgery with ultra-high resolution, real-time, advanced imaging tools that address unmet medical needs. A Toronto-based company established in 2013, with U.S. headquarters in Dallas, Texas, Perimeter seeks to harness the power of big data, artificial intelligence, and machine learning technology to further its mission of improving the standard of care, providing better long-term outcomes for patients, and reducing healthcare costs.Perimeter’s proprietary Optical Coherence Tomography (OCT) technology provides high-definition, 3D images of margins in the operating room. This has the potential to give surgeons clarity on margin status so they can make decisions to take more tissue at the point of care, not days later when pathology reports come back.

Comprised of 23 hospitals, more than 2,500 physicians, and over 1600 physician and specialist offices across greater Atlanta and North Georgia, Piedmont Healthcare is a fast-growing, recognized leader in delivering expert care. Metro Atlanta’s vibrant economy fuels a wealth of global communities and diverse cultural experiences, while the state of Georgia offers coastline beaches and mountain views. Live and work with the best at Piedmont in the big and small towns of the Peach State.

DCISionRT by PreludeDx is the only DCIS test that predicts radiation therapy (RT) benefit in women undergoing breast conserving surgery (BCS). The test provides a Decision Score along a continuum from 0 to 10, that stratifies a woman’s 10-yr risk of local recurrence as low, elevated or residual risk. DCISionRT combines seven biomarkers and four clinicopathologic factors, using a non-linear algorithm to account for multiple interactions between individual biologic factors to provide a better assessment of the patient’s individual tumor biology. The personalized results help patients and physicians make more informed treatment decisions and facilitate the shared decision-making process.

The Radialis PET Imager brings unprecedented accuracy and 3D resolution to functional imaging for determining the regional extent of disease. Recent studies demonstrate both high sensitivity and specificity for malignancy.

High definition breast PET imaging shows promise: -for cases where MRI may have been otherwise been ordered only due to breast density; -for assessing residual disease following neoadjuvant systemic therapy; -for de-escalating treatment conundrums, and -for visualizing invasive lobular carcinoma with appropriate radiotracers.

The Radialis system is FDA 510(k) cleared with an applicable CPT code for use in treatment planning and has a small footprint to be easily sited either within current nuclear medicine facilities or to broaden the accessibility of PET.

The maker of the RecoverEasy Shower Cape, RecoverEasy designs and sells surgery recovery products to enhance the surgery recovery experience from a functional, esthetic, and emotional perspective.

Loss of sensation following mastectomy and breast reconstruction can have a major impact on your patients’ lives. Resensation® is a surgical nerve repair technique that can help your patients look–and feel–like themselves again.

Ronin Surgical Corp. -- makers of the X6 Surgical Headlight System. The wireless X6 is the lightest, brightest, longest-running operating room surgical headlight on the market. Contact Ronin Surgical today at +1.415.226.9414 or Contact@RoninSurgical.com. Ronin Surgical: Designed Without Compromise. www.RoninSurgical.com

Histolog Scanner - Rapid, high-resolution interoperative margin assessment. Confocal microscopy in the surgical suite. Shown to reduce reoperations from 30% to 10% in highly complex patient populations.

Silbiotech featuring the BBDRisk Dx® Test. The BBDRisk Dx® Test (Benign Breast Disease Risk) is a new tumor biology based genomic test designed to address the dilemma in treating atypical hyperplasias. Studies show that ~20% of atypical patients develop cancer. The BBDRisk Dx® Test assesses multiple cancer markers in FFPE atypical tissues by IHC, generates a ‘Risk Score’ from 0-10 and categorizes the patient into a Low, or High Risk group. Cancer rates in the low risk group are less than 3% over 15 years. Cancer rates in the high risk group are more than 91%. BBDRisk Dx® was validated in 550 clinical samples. BBDRisk Dx® offers for the first time assessment of a patient’s personalized risk level. Clinicians can now make informed treatment decisions in managing atypias.

Visit SimBioSys: Advancing Breast Surgery with AI and Spatial Intelligence SimBioSys is transforming breast cancer care by helping surgeons see tumors in a whole new dimension. Our TumorSight™ platform uses AI and spatial biophysics to generate FDA-cleared 3D visualizations of tumor extent, delivering detailed insights into size, shape, and location that go beyond traditional imaging. TumorSight™ Viz supports more informed, personalized surgical planning—giving you a deeper understanding of each patient’s tumor to guide precision in the OR. Developed in collaboration with leading academic institutions, SimBioSys bridges the gap between science and surgical practice—empowering breast surgeons to deliver more confident, individualized care. Visit us at Booth #123 to see how SimBioSys can help elevate your surgical precision and patient outcomes. Learn more: https://simbiosys.com/.

Somavac is transforming the post-surgical care of women undergoing mastectomy and breast reconstruction by providing a negative pressure therapy system to efficiently remove surgical fluids and prevent seromas. Our novel negative pressure therapy is a closed system which eliminates the need for the handling of bodily fluid required by JP Bulbs. By maintaining continuous negative pressure, Somavac has demonstrated that drains can be removed 30% sooner –improving the patient’s quality of life by reducing stress and the risk of post-operative complications. Somavac attaches to standard surgical drains and does not require a change in surgical technique. Patients gain mobility and comfort through our discreet system which attaches like a belt – no more leaking, safety pins, or dangling bulbs. Somavac is FDA-cleared and has improved the lives of 1200+ patients already.

Still is an Aesthetic Flat Closure advocacy project that creates awareness of AFC as a reconstruction option and promotes flat visibility and body positivity.

While breasts can serve as a symbol of femininity, they are not the definition of what it means to be a woman or the only way to feel feminine. Women who choose to go flat after mastectomy exemplify beauty, empowerment, strength, love, compassion, empathy, and so much more. All of this shines through—sans breasts.

Still illustrates this truth through photography and storytelling—showing how those who make this reconstruction choice are still themselves—still strong, still beautiful... STILL.

Sutter Health is a not-for-profit, people-centered healthcare system providing comprehensive care throughout California. Sutter Health is committed to innovative, high-quality patient care and community partnerships. Today, Sutter Health is pursuing a bold new plan to reach more people and make excellent healthcare more connected and accessible. The health system’s 57,000+ staff and clinicians and 12,000+ affiliated physicians currently serve more than 3 million patients with a focus on expanding opportunities to serve patients, people and communities better. Sutter Health provides exceptional, affordable care through its hospitals, medical groups, ambulatory surgery centers, urgent care clinics, telehealth, home health and hospice services. Dedicated to transforming healthcare, at Sutter Health, getting better never stops. Learn more about how Sutter Health is transforming healthcare at sutterhealth.org and vitals.sutterhealth.org.

The US Oncology Network believes local cancer care is better care. We empower the delivery of advanced integrated cancer care through our network of independent physicians who share expertise and resources to provide quality, value-based care close to home.

Thompson Retractor is the global leader in innovative table-mounted retractor systems, delivering exceptional customer service and timely product solutions tailored to your needs. The Thompson is engineered for a variety of surgical specialties, ensuring optimal visualization, low-profile instruments which minimize obstruction and provide a clearer view of the surgical site, and ultimate versatility with a highly customizable frame that adapts to all your exposure needs.

Vector Surgical is the global leader in tissue orientation devices that provide the most accurate designation of excised tissue margins in cancer surgery. Our devices integrate the needs of surgeons, pathologists and radiologists, providing tools that enable the highest level of care for their cancer patients. Leading hospitals and physicians are eliminating error and improving outcomes with our products: MarginMarker sterile ink kits, CorrectClips radiographic clips and the SilversteinWrap.

Videra Surgical is an oncology surgery company focused on breast cancer treatment with our tumor bed marker, VeraForm®. We strongly believe that helping radiation oncologists better identify the tumor bed is essential for the continuum of care for breast cancer patients. VeraForm is an adaptable tissue marker comprised of a radiopaque filament that provides a continuous, 3D, multi-plane and permanent mark of a tumor bed. VeraForm is easily viewed by the radiation oncologist under X-ray and CT/CBCT, but it does not create artifact in MRI or ultrasound, as it is completely metal-free. VeraForm is 510(k) cleared and has been placed in thousands of patients in a rapidly growing number of U.S. centers. VeraForm is designed to provide a precise depiction of the tumor bed, allowing radiation oncologists to be more targeted in the delivery of radiation, in an attempt to avoid over-radiating and possibly damaging collateral tissue and organs.

View Point Medical is proud to present the OneMark® Detection Imaging System –a non-invasive localization platform to aid surgeons and radiologists in advancing outcomes in breast surgery via improved patient experience, radiologic efficiency, and surgical site centering.

At Wellstar, people are at the center of everything we do and every decision we make. As a not-for-profit organization, we have made a generational commitment to transform healthcare for all. We work to ensure every person has access to personalized care that helps them spend more time being a person, rather than a patient. That’s what we mean when we say we’re more than healthcare–we’re PeopleCare.

Wellstar is nationally recognized for our inclusive culture, exceptional doctors and team members, and personal, high-quality care. We thoughtfully reinvest in prevention, wellness programs and charity care, and provide access to compassionate, world-class care through our expansive system of 11 hospitals, 329 medical office locations, 11 cancer centers, 91 rehabilitation centers, 35 imaging centers, 20 urgent care locations, five health parks, three hospice facilities and two retirement villages. To learn more about how we care for the communities we serve, visit wellstar.org.

XpediteMD is a cloud-based, comprehensive digital oncology patient navigation and care management software platform that improves patient outcomes while significantly increasing practice revenue using New Navigation CPT Codes. Find out more by registering for our ASBrS Vendor Symposium at www.XpediteMD.com/asbrs

ZEISS offers future-oriented technologies for intraoperative radiotherapy. The INTRABEAM system, which can be managed by the single radiation oncologist, enables a targeted, risk-adapted and interdisciplinary treatment of tumors. A shortened overall treatment regime can reduce associated side-effects and enhance the comfort of the comfort for the patient.